#ASCO25 #plenary If the graph on the left is practice changing, the graph on the right is urgently practice changing. Cost to health systems-$15K to $18K a month vs $100-$150 a month. ATOMIC trial vs CHALLENGE trial.

x.com/i/article/1929…

Most viewed this week from JAMA Oncology: Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. ja.ma/45zBluy

Good morning all. After yesterday's excitement about the CHALLENGE exercise trial, here is my critical appraisal on Sensible Medicine #ASCO25

Phase 2 study of pembrolizumab added to chemoradiation therapy in #vulvarcancer w cisplatin yields 75% response rate and manageable AE #ASCO25 #gyncsm

Just out: Myeloma mSMART recommendations for prevention and management of CAR-T related toxicities including CRS, neurotoxicity, cytopenias, and more. Yi Lin #ASCO25 Cilta-cel, Ide-cel msmart.org/mm-treatment-g…

How to improve outcome in advanced ovarian epithelial cancer post 1st line chemotherapy and sx ? Add IO or parp inhibitors or both or none ? Money slide to summarize all 4 new trials in this space. Taken from #ASCO25 ASCO Kate Sears OncoAlert

New Impact Factors of Leading Journals in Gynecologic Oncology

I have strongly advocate for supplemental Mg++ against AKI during HIPEC. Among 13 719 pct treated w/ IV CDDP, IV Mg++ was associated w/ 20% lower adjusted odds of developing AKI. Findings also supported by multiple sensitivity and secondary analyses! jamanetwork.com/journals/jamao…

🎯 Platinum-Resistant Ovarian Cancer (PROC): all trials data . 🧯 Monotherapy in control arms (non-taxane chemo): JAVELIN 200 → PLD: ORR 4%, mPFS 3.5 FORWARD I → PLD/topotecan: ORR 6%, mPFS 3.2 CORAIL → PLD/topotecan: ORR 12%, mPFS 3.6 NINJA → gemcitabine/PLD: ORR 13%, mPFS

13.6% in uterine serous carcinoma

Adjuvant ET in EBC = Individualised Approach Nice article from ESMO

As tomorrow is 1st day of hem/onc fellowship for many- thought i’d reshare this little piece as to what i would tell myself if i were starting fellowship now (which sounds attractive… all that black hair …) ☑️Stay curious ☑️Remain humble ☑️Be positive ☑️Build and enjoy your

Exercizumab is real. Aerobic exercise cut colon cancer recurrence + death. It’s time to combine movement with medicine not one or the other. #oncology #Cancer NEJM OncoAlert ASCO #ASCO25 DOI: 10.1056/NEJMoa2502760

Organ preservation in dMMR #ColonCancer? YES, but carefully. 🧬 Neoadj. immunotherapy shows high CR rates & safety 🧓 Ideal for frail pts, high-surgical-risk, or pt preference 📋 Requires strict selection: ▪️ Non-obstructive ▪️ Tumor-negative biopsy ▪️ ctDNA/PET-CT guidance ▪️

This is a very well researched and well written article on toxicities of cancer drugs. medscape.com/viewarticle/on…

The latest Diary of an Oncology Leader video is out. In this episode, Angela Lamarca shares her thoughts on resilience, problem-solving, and balancing work and life in oncology. 📹 Watch now to get inspired. 🔗 ow.ly/CMzB50WF3ug #W4O #OncologyLeadership

Tamoxifen and Uterine Cancer Link 💥Tmx-associated ECs show fewer PIK3CA mutations, as tmx itself activates the ER–IGF1R–PI3K pathway in the uterus. 📌An example of therapy-induced carcinogenesis via signaling activation rather than mutagenesis👇 nature.com/articles/s4158…

Development of chronic kidney disease after cisplatin chemotherapy use JAMA Oncology. In over 9000 pts, 13.6% of pts developed CKD. Estimated glomerular filtration rate decreased by mean of 8.1 mL/min/1.73m2 and low baseline eGFR was greatest predictor of CKD. jamanetwork.com/journals/jamao…

Her2 Testing in Endometrial Cancer 60% do express via IHC. 1/3rd would be Her2 3+ or HER2 2+/FISH +ve and potentially qualify for current NCCN listed HER2 directed ADCs. HER2 IHC testing should be considered in all endometrial tumors